Beste Astellas podcaster (2024)

1
Emergent donates 50k doses of mpox vaccine to Africa, FDA rejects Regeneron blood cancer bispecific antibody, China indicts Astellas exec for espionage [The good, the bad, the ugly] 3:41

10d ago3:41

3:41

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Emergent donates 50,000 doses of mpox vaccine to Africa The bad — FDA rejects Regeneron blood cancer bispecific antibody The ugly — China indicts Astellas exec for espionage…

1
S07 E10: Astellas’ Tadaaki Taniguchi on how to challenge the status quo 28:43

24d ago28:43

28:43

In this season finale of the EMJ GOLD podcast, Isabel speaks to Dr Tadaaki Taniguchi, Chief Medical Officer, Head of Medical and Development, Astellas Pharma, about how he strives to challenge the status quo in the pharmaceutical industry. The two discuss how Tadaaki’s time as a surgical oncologist has influenced his leadership style, how collabora…

1
Ep 67 - AAM's Craig Burton on Opportunities, Challenges of U.S. Biosimilars Market 28:51

11h ago28:51

28:51

There is good news in this year’s Association for Accessible Medicines report on savings from biosimilars, including a 30% increase over the last year in savings attributed to biosimilars. The report also explores the economic, policy and regulatory headwinds that are preventing the industry from generating savings at a level that would have a dram…

1
The Science of Sleep: Unmet Needs and Treatments for Narcolepsy ft. Avadel Pharma’s Dr. Jennifer Gudeman 33:38

2d ago33:38

33:38

In this episode, Ayesha spoke with Jennifer Gudeman, Pharm D, Senior Vice President, Medical and Clinical Affairs, Avadel Pharmaceuticals plc, a biopharmaceutical company working on innovative solutions to the development of medications that disrupt treatment paradigms and address unmet needs. The company is currently focused on developing treatmen…

1
FDA approves Illumina cancer biomarker test, BioMarin reveals more layoffs, FDA hits API maker Global Calcium with 483 [The good, the bad, the ugly] 3:30

2d ago3:30

3:30

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA approves Illumina cancer biomarker test The bad — BioMarin reveals more layoffs The ugly — FDA hits API maker Global Calcium with 483Av Pharma Manufacturing

1
Pharma’s new age of longevity 4:15

8d ago4:15

4:15

The concept of healthspan has recently gained new attention in the pharma industry and rightfully so, given the surprisingly large chasm in the U.S. between average years lived (77.5) and average years lived in good health (63.9). Facing a growing demographic of unhealthy seniors, a handful of innovative biotechs are reframing the longevity discuss…

1
Non-Hormonal Innovations in Obesity and Diabetes Treatment with Aphaia Pharma’s Dr. Steffen-Sebastian Bolz 42:30

9d ago42:30

42:30

In this episode, Ayesha spoke with Steffen-Sebastian Bolz, MD, PhD, a scientist, physician and entrepreneur. He is a Co-Founder of Aphaia Pharma AG and Founder and Chief Scientific and Medical Officer at Qanatpharma AG. Dr. Bolz holds a full professorship at the University of Toronto, is a Principal Investigator at the Ted Rogers Centre for Heart R…

1
Popular Episode - Bob Nelsen on AI, China and the IRA 35:33

14d ago35:33

35:33

This is a previously recorded episode of The BioCentury Show from February 22, 2024. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes. In a wide-ranging conversation with BioCentury, Bob Nelsen, co-founder and managing director of Arch Venture Partners, said he is excited…

1
FNIH Study Shows Promise of Blood Tests for Alzheimer’s Disease, featuring Dementia Expert Dr. Schindler and FNIH Neuroscience Director Dr. Travaglia 36:43

16d ago36:43

36:43

In this episode, Ayesha spoke with Alessio Travaglia, PhD, neuroscientist and Director Neuroscience at the Foundation for the National Institutes of Health (FNIH) and Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University. Results from a head-to-head study led by the FNIH Biomarkers Consortium, with data analysis led …

1
FDA approves Ascendis drug, Lykos PTSD treatment rejected, Novartis bid blocked [The good, the bad, the ugly] 3:21

17d ago3:21

3:21

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA approves Ascendis hypoparathyroidism drug The bad — FDA rejects Lykos MDMA PTSD drug The ugly — Judge blocks Novartis bid to stop generic blockbuster heart drug…

1
Advancing Medicine With Placenta-Derived Cells with Dr. Robert Hariri 1:00:35

21d ago1:00:35

1:00:35

🎙ABOUT DR. ROBERT HARIRI: Dr. Bob Hariri is a pioneering surgeon, biomedical scientist, and serial entrepreneur with expertise in biomedicine and aerospace. He is the founder, chairperson, and CEO of Celularity, Inc., a leader in human cellular therapeutics, and previously founded Anthrogenesis Corporation, which was acquired by Celgene, where he s…

1
Beyond the Beat: Dr. Matthew Martinez Discusses HCM Care in Athletes and New Camzyos Guidelines 39:15

23d ago39:15

39:15

In this episode, Ayesha spoke with Matthew Martinez, MD, a board-certified cardiologist and nationally recognized expert in hypertrophic cardiomyopathy (HCM). He serves as director of Atlantic Health System Sports Cardiology and the director of the Chanin T. Mast Center for Hypertrophic Cardiomyopathy. Dr. Martinez is the Chair of ACC online “LEARN…

1
Amneal's Parkinson's pill approved, Novo Nordisk withdraws Wegovy approval expansion bid, FDA delays BeiGene Tevimbra decision [The good, the bad, the ugly] 2:59

24d ago2:59

2:59

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Amneal gets FDA nod for Parkinson’s pill The bad — Novo Nordisk withdraws bid for Wegovy label expansion in heart failure The ugly — FDA delays decision on BeiGene Tevimbra as a first-line therapy…

1
Ep. 66 - Jane Grogan on Building Biogen’s Growth Engine 32:23

28d ago32:23

32:23

As Jane Grogan anticipates the unmet needs in patients five years from now, she’s harnessing a wave of interest in targeting B cells as a key driver of an immunology expansion at Biogen. In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, Grogan, who became EVP and head of research of Biogen in October, discusses how she’s …

1
Driving Better Outcomes with Ambulatory Surgical Centers 54:26

28d ago54:26

54:26

ABOUT ARIC BURKE Aric brings over eighteen years of experience in ASC consulting, development, and operations. He oversees the strategic vision, operational management, and organizational structure of Atlas, driving its profitability and strategic direction. Before founding Atlas, Aric was the West Market President for United Surgical Partners Inte…

1
The Future of Patient-Centricity: Advancing Frameworks to Achieve Greater Impact 31:00

29d ago31:00

31:00

For more information, visit patientsaspartners.org.Av Pharma Talk Radio

1
Bridging Science and Advocacy with Lawreen Asuncion, Life Science Professional and Rare Disease Patient Advocate 33:48

30d ago33:48

33:48

In this episode, Ayesha spoke with Lawreen Asuncion, a patient advocate who works to raise awareness for the rare disease Usher syndrome. Lawreen has worked professionally in the biotech and life science markets for over 25 years. She provides input and perspectives for rare genetic disease programs and clinical trials sponsored by biotech and phar…

1
Using AI to Accelerate the Next Generation of Oncology Immunotherapies 43:00

30d ago43:00

43:00

For more information, go to IO360summit.com.Av Pharma Talk Radio

1
S07 E09: Taking control of customer experience 10:55

1M ago10:55

10:55

In this penultimate episode of Season 7, Isabel and Jade sit down to discuss EMJ GOLD’s most recent features of the month – our infographic on optimising pharma’s customer experience journey and an article on how exactly to design this experience. Within the episode, the team explore how the industry may be missing out on insights gathered from HCP…

1
FDA approves Adaptimmune therapy, halts vTv diabetes program; Sanofi sues Sarepta over Duchenne patents [The good, the bad, the ugly] 3:58

1M ago3:58

3:58

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA approves Adaptimmune engineered cell therapy The bad — FDA puts clinical hold on vTv Therapeutics diabetes program The ugly — Sanofi sues Sarepta over manufacturing patents for Duchenne gene ther…

1
Bringing Integrated Nutritional and Pharmaceutical Approaches to the Table for GI Health with Nestlé Health Science’s Moreno Perugini 36:26

1M ago36:26

36:26

In this episode, Ayesha spoke with Moreno Perugini, President of Active & Medical Nutrition, US & President of Global Pharmaceutical Therapies at Nestlé Health Science US. As President of Global Pharmaceutical Therapies, Moreno and his team actively shape the healthcare system through innovative approaches and a strong commitment to delivering phar…

1
S07 E08: ViiV Healthcare’s Harmony Garges on giving voice to people with HIV 15:32

1M ago15:32

15:32

In this week’s edition of the podcast, Isabel and Jade share an interview with Dr Harmony Garges, Chief Medical Officer, ViiV Healthcare. She speaks with Dr Jonathan Sackier, Host, EMJ Podcast, who joined us in Reuters Barcelona where we meet our guest. Together, the two discuss Harmony’s decision to join the pharmaceutical industry, how treating c…

1
FDA approves Sun Pharma hair loss drug, FDA issues warning letter to Brassica, EMA rejects Eisai-Biogen Alzheimer's drug [The good, the bad, the ugly] 3:46

1M ago3:46

3:46

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA approves Sun Pharma hair loss drug The bad — FDA issues harsh warning letter to Indian CDMO Brassica The ugly — EMA issues negative opinion on Eisai-Biogen Alzheimer's drug…

1
Immuno-Oncology Cell Therapy Data Analytics: What and How to Measure 22:00

1M ago22:00

22:00

For more information, visit theconferenceforum.org.Av Pharma Talk Radio

1
Ep. 65 - Astellas' Claus Zieler: Global Launches with Local Impact 32:27

1M ago32:27

32:27

As Astellas prepares to launch four products in parallel, Chief Commercial Officer Claus Zieler is balancing the complexity of this multi-faceted enterprise with a simple guiding principle: it has to work at a local level, and that will change with geography, circumstance and time. In conversation with Editor in Chief Simone Fishburn on The BioCent…

1
What to Expect at CRAACO: Clinical Research as a Care Option 2024, in 5 Minutes 5:00

1M ago5:00

5:00

Summary: The 2024 CRAACO: Clinical Research as a Care Option conference is a unique opportunity for pharma, healthcare and patients to come together and address how we can integrate healthcare and clinical research to improve patient access to clinical trials. In this short podcast, Valerie Bowling, Executive Director of the Conference Forum, outli…

1
S07 E07: Kyowa Kirin’s Danie du Plessis on the potential of patient partnerships 29:35

1M ago29:35

29:35

In this week’s episode, Danie du Plessis, Executive Vice President, Pharmaceutical Operations, Kyowa Kirin, sits down with the EMJ GOLD team to share the value that patient partnerships can hold in the industry. Danie explores how patient partnerships have evolved over the years, what companies should be doing to get them to their best potential, t…

1
Innovating Approaches to Target Diseases of Aging with Jerry McLaughlin, CEO of Life Biosciences 29:30

1M ago29:30

29:30

In this episode, Ayesha spoke with Jerry McLaughlin, chief executive officer and board member of Life Biosciences, a company advancing innovative cellular rejuvenation platforms to reverse diseases of aging. Life Biosciences is developing a gene therapy for primary open-angle glaucoma (POAG) and non-arteritic anterior ischemic optic neuropathy (NAI…

1
How to Enhance Clinical Trial Participation in Diverse Linguistic Backgrounds 37:00

1M ago37:00

37:00

For more information, visit patientsaspartners.org.Av Pharma Talk Radio

1
Genentech's oral weight loss drug shows promise; FDA denies accelerated approval for Agenus' cancer drug; Orexo's opioid overdose drug rejected again [The good, the bad, the ugly] 3:35

2M ago3:35

3:35

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Genentech's oral weight loss drug shows promise The bad — FDA denies accelerated approval for Agenus' cancer drug The ugly — Orexo's opioid overdose drug rejected again…

1
S07 E06: AZ’s Stefan Woxström on why without health, we don’t have anything 40:41

2M ago40:41

40:41

Tune in to the latest episode of the EMJ GOLD podcast as Isabel and Jade cross the halfway point of the season with special guest host Dr Jonathan Sackier of the EMJ podcast. In this episode, the team listen back to Jonathan's discussion with Stefan Woxström, Senior Vice President Europe and Canada, AstraZeneca at Reuters Events: Pharma 2024 in Bar…

1
Golden Innovations: Nanocrystal Therapies for ALS and MS with Clene Nanomedicines’ Dr. Karen Ho 34:11

2M ago34:11

34:11

In this episode, Ayesha spoke with Karen S. Ho, PhD, Vice President, Translational Medicine at Clene Nanomedicine, a biopharmaceutical company focused on developing treatments for neurodegenerative diseases to restore and protect neuronal health and function. Clene Nanomedicine is developing nanotherapeutics that target cellular energy impairments …

1
Patient Engagement Advocate on Collaborating Successfully with Pharma 25:00

2M ago25:00

25:00

For more information, visit theconferenceforum.org.Av Pharma Talk Radio

1
Pfizer advances obesity pill, FDA rejects Novo insulin, FTC releases PBM report [The good, the bad, the ugly] 3:28

2M ago3:28

3:28

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Pfizer advances once-daily obesity pill The bad — FDA rejects Novo Nordisk once-weekly insulin The ugly — FTC releases long-awaited report on PBMsAv Pharma Manufacturing

1
Ep. 64 - NPC CEO John O’Brien: Why America Needs an Honest Conversation About Drug Pricing 33:36

2M ago33:36

33:36

Ignorance about the path from scientific discovery to approved drugs, high out-of-pocket costs, and a byzantine healthcare system that obscures net prices while inflating list prices have fueled policies that threaten biomedical progress, John O’Brien, CEO of think tank National Pharmaceutical Council, told BioCentury. In an interview with The BioC…

1
From Symptoms to Solutions: Transforming Menopause Treatment with Marci English of Astellas Pharma 28:17

2M ago28:17

28:17

In this episode, Ayesha spoke with Marci English, Vice President and Head of BioPharma Development at Astellas Pharma about a groundbreaking new treatment that addresses the underlying mechanisms of menopause symptoms. In May 2023, Astellas received FDA approval for fezolinetant (commercial name Veozah) for the treatment of moderate to severe vasom…

1
S07 E05: Sandoz’s Claire D’Abreu-Hayling on leading with love 19:54

2M ago19:54

19:54

This week, Claire D'Abreu-Hayling, Chief Scientific Officer, Sandoz, joins Isabel on the podcast to share how leading with love rather than ruling with an iron fist is the best way to get results in the pharmaceutical industry. In this episode, Claire and Isabel discuss how she fell in love with science as a child, the leadership skills she has gai…

1
What to Expect at DPHARM 2024, with DPHARM Directors 10:00

2M ago10:00

10:00

For more information, visit DPHARMconference.com.Av Pharma Talk Radio

1
Lilly Alzheimer’s drug gets full approval, Rocket gene therapy rejected, Eisai, BMS end ADC partnership [The good, the bad, the ugly] 3:44

2M ago3:44

3:44

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA grants Eli Lilly Alzheimer’s drug full approval The bad — FDA rejects Rocket gene therapy The ugly — Eisai, BMS end ADC partnershipAv Pharma Manufacturing

1
Astellas Head of Patient Centricity on Patient-Centric Medicine Development 26:00

2M ago26:00

26:00

For more information, visitpatientsaspartners.orgAv Pharma Talk Radio

1
[Solutions Spotlight] Streamlining oral dose packaging design 31:57

2M ago31:57

31:57

By integrating a Quality by Design (QbD) approach, developers can design robust packaging from the outset, drastically reducing development time and costs. Understanding how moisture affects a product is key, allowing developers to use industry-accepted and validated models to predict and address potential stability issues early in the design phase…

1
S07 E04: How creativity and innovation are revolutionising medical education 11:10

2M ago11:10

11:10

Join EMJ GOLD for a special edition of the podcast, in which Isabel is joined by Tim Uden, Creative Director, EMJ to discuss the new frontier of medical education tools and skills. In this episode, the two explore how new technological offerings, such as interactive articles, are transforming the space for medical content – enabling content creator…

1
New Frontiers in MASH and Chronic Liver Diseases with Aligos CEO Dr. Lawrence Blatt 34:59

2M ago34:59

34:59

In this episode, Ayesha spoke with Lawrence Blatt, PhD, MBA, Chairman and CEO of Aligos Therapeutics, a company developing targeted therapies for liver diseases like MASH (metabolic dysfunction-associated steatohepatitis) and viral diseases to address important unmet medical needs. Prior to co-founding Aligos Therapeutics, Dr. Blatt served as the G…

1
Verona wins COPD nod, FDA rejects Merck-Daiichi ADC, Glenmark recalls potassium chloride capsules [The good, the bad, the ugly] 3:42

2M ago3:42

3:42

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Verona wins FDA nod for COPD The bad — FDA issues CRL to Merck-Daiichi lung cancer ADC The ugly — Glenmark recalls 114 batches of potassium chloride capsules…

1
Ep. 63 - Day One's Jeremy Bender: Building Pediatric Oncology from the Ground Up 32:27

2M ago32:27

32:27

Pediatric cancer drug development is difficult: it requires high levels of safety, involves parents as well as the patients, and has small populations that can make it difficult to achieve the revenues that reward the investment. Squaring that circle, according to Day One Biopharmaceuticals CEO Jeremy Bender, is not impossible, but takes a dedicate…

1
FNIH’s Dr. Travaglia and ALS Patient Advocate Dr. Sethi Discuss New ALS Program 30:10

2M ago30:10

30:10

In this episode, Ayesha spoke with Alessio Travaglia, PhD, Director Neuroscience at the Foundation for the National Institutes of Health (FNIH) who also manages FNIH’s new Accelerating Medicines Partnership in Amyotrophic Lateral Sclerosis (AMP ALS) program, and Nadia Sethi, DDS, an ALS patient advocate who formerly served as Director of Community …

1
Pride Special: J&J's Edmond Chan on the value in being your authentic self 18:18

2M ago18:18

18:18

As we approach the end of Pride month, Jade explores how the pharmaceutical industry can best support staff and patients who identify as part of the LGBTQ+ community. She talks with Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology, J&J, who shares his personal views on how the industry can improve health outcomes and encou…

1
Gilead HIV shot delivers zero infections, Takeda epilepsy drug misses endpoints, Lilly goes after counterfeiters [The good, the bad, the ugly] 3:36

2M ago3:36

3:36

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Gilead twice-yearly HIV shot delivers zero infections in trial The bad — Takeda epilepsy drug misses endpoints in trials The ugly — Eli Lilly goes after counterfeiters…

1
Preferences in Decentralization and Digitalization of Pediatric Clinical Trials 26:00

2M ago26:00

26:00

For more information, visit theconferenceforum.org.Av Pharma Talk Radio

1
Working with IDNs: The Pharma Perspective 1:12:50

3M ago1:12:50

1:12:50

ABOUT HEALTH CARE ROUNDS Health Care Rounds is a weekly podcast developed for health care leaders who are at the forefront of health care delivery and payment reform. Join Darwin Research Group founder and CEO John Marchica as he discusses the latest advancements in health care business news and policy developments. ABOUT MATT PORTCH Matt Portch is…

Podcaster verdt å lytte til

Astellas Podcaster

Podcaster verdt å lytte til

Hurtigreferanseguide